Preclinical data for reversible BTK inhibitor ... - CLL Support

CLL Support

22,370 members38,477 posts

Preclinical data for reversible BTK inhibitor RXC005

Myrddin profile image
2 Replies

Preclinical data for reversible BTK inhibitor RXC005 presented at the 17th International Workshop of Chronic Lymphocytic Leukemia

15 May 2017

The poster, entitled "RXC005, a Potent and Selective, Reversible BTK Inhibitor Targeting both Wild-type and Mutant C481S BTK with Potent Efficacy in ABC-DLBCL Xenograft Mouse Models", demonstrated that RXC005 successfully inhibits wild-type BTK and C481S mutant BTK, as well as B-Cell Receptor signalling in ABC-DLBCL cell lines and importantly primary CLL cells.

redxpharma.com/news/2017/20...

Written by
Myrddin profile image
Myrddin
To view profiles and participate in discussions please or .
2 Replies
Justasheet1 profile image
Justasheet1

Still a few years away but I love ❤️ progress. Thanks for posting

Jeff

Myrddin profile image
Myrddin in reply to Justasheet1

Certainly will be a while before trials and any approval but good to see the development of next generation candidates are underway. We need as many options as possible when treatment needed especially with side effects and resistance in the mix.

You may also like...

A Conversation with Dr Tam about Zanubrutinib: A Novel BTK Inhibitor

-2019/zanubrutinib-a-novel-btk-inhibitor-in-chronic-lymphocytic-leukemia-and-non-hodgkin-lymphoma/...

Do btk inhibitors kill neurophils?

I am reluctant to start taking btk inhibitors, despite being told I have astronomically high wbc,...

ACP-196 (BTK inhibitor acalabrutinib) Trial

From EHA June 2022. Treating hypertension in patients receiving BTK inhibitors

reating-hypertension-in-patients-receiving-btk-inhibitors/ Jackie

Second-Generation BTK Inhibitors Hit the Treatment Bullseye With Fewer Off-Target Effects

in that they involve sustained distal B-cell receptor signaling through PIK3-AKT (protein kinase B)...